AJO International最新文献

{"title":"Solitary fibrous tumor of the eyelid","authors":"Samantha D Butterfield , David Zlotnick , Rona Z Silkiss","doi":"10.1016/j.ajoint.2024.100050","DOIUrl":"10.1016/j.ajoint.2024.100050","url":null,"abstract":"","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100050"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000509/pdfft?md5=c4684f1269e94e0ff83a56785c15f2cd&pid=1-s2.0-S2950253524000509-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141715428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optic cup morphology associated with glaucomatous damage: Findings from the Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study","authors":"Anusha Mamidipaka ,&nbsp;Isabel Di Rosa ,&nbsp;Patrick Augello ,&nbsp;Yineng Chen ,&nbsp;Rebecca Salowe ,&nbsp;Yan Zhu ,&nbsp;Victoria Addis ,&nbsp;Prithvi Sankar ,&nbsp;Ebenezer Daniel ,&nbsp;Gui-Shuang Ying ,&nbsp;Joan O'Brien","doi":"10.1016/j.ajoint.2024.100053","DOIUrl":"10.1016/j.ajoint.2024.100053","url":null,"abstract":"<div><h3>Purpose</h3><p>While it has been well established that advanced glaucoma is associated with a large cup-to-disc ratio (CDR), it is not known if the shape of the cup, particularly excavated cups with expanded lower portions (bean-pot cups), play any additional role in glaucomatous damage. We investigated this among individuals of African ancestry, a population that is more vulnerable to glaucoma than any other ethnic group.</p></div><div><h3>Design</h3><p>Case-control study</p></div><div><h3>Methods</h3><p> <!--> </p></div><div><h3>Setting</h3><p>Institutional (University of Pennsylvania)</p></div><div><h3>Subjects</h3><p>3,255 eyes from 1,734 glaucoma cases from the Primary Open-Angle African American Glaucoma Genetics (POAAGG) study.</p></div><div><h3>Procedure</h3><p>Two graders independently assessed quantitative and qualitative aspects of the optic cup, with any discrepancies adjudicated by an ophthalmologist. The predominant cup shape (&gt;50 %) was chosen in cases in which features of two or more cup shapes were present in the same eye. Comparisons of demographic and ocular characteristics among three cup shape groups (conical, cylindrical, and bean-pot) performed using generalized linear models, and generalized estimated equations applied to account for inter-eye correlation.</p></div><div><h3>Main Outcome Measures</h3><p>Qualitative features of cup shape and phenotypic traits, in conjunction with demographic and genetic information.</p></div><div><h3>Results</h3><p>Of 3,255 eyes, a total of 1,339 (41.1 %) exhibit a conical cup shape, 1,470 (45.2 %) have a cylindrical cup shape, and 446 (13.7 %) display a bean-pot cup shape. Compared to other cup morphology, bean-pot cups are significantly associated with lower MD, larger CDR, higher IOP, thinner RNFL, and worse VA in logMAR (all <em>p</em> &lt; 0.001). Genetic analysis does not show any association between various genetic variants and cup shape. Factors independently predictive of bean-pot cupping include younger age at diagnosis (aOR 0.96 per 1 year increase in age of enrollment, <em>p</em> &lt; 0.0001), CDR (adjusted odds ratio (aOR) 1.87, <em>p</em> &lt; 0.0001), and the presence of certain optic disc features, including visible pores in the LC (aOR 2.76, <em>p</em> &lt; 0.0001), nasalization of vessels (aOR 2.64, <em>p</em> &lt; 0.0001), and vessel bayonetting (aOR 2.94, <em>p</em> &lt; 0.0001).</p></div><div><h3>Conclusion</h3><p>This study shows the clinical significance of different cup shapes in glaucoma in an African ancestry population and suggests that bean-pot cups are associated with the most severe glaucomatous damage, independent of cup-disc ratio. This association should be considered when determining prognosis following glaucoma interventions.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000534/pdfft?md5=8de5b89f3b1094cde00b22c7bbb989c3&pid=1-s2.0-S2950253524000534-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3-year safety and efficacy results of PreserFlo™ Microshunt in glaucoma patients: A multicentre European cohort study","authors":"Karl Mercieca ,&nbsp;Raj Bhayani ,&nbsp;Jose Maria Martinez-de-la-Casa ,&nbsp;Michele Figus ,&nbsp;Karsten Klabe ,&nbsp;Alessandro Rabiolo ,&nbsp;Constance Weber","doi":"10.1016/j.ajoint.2024.100054","DOIUrl":"10.1016/j.ajoint.2024.100054","url":null,"abstract":"<div><h3>Purpose</h3><p>To report three-year outcomes of a multicenter cohort undergoing Preserflo Microshunt surgery (PFMS).</p></div><div><h3>Design</h3><p>Retrospective cohort study</p></div><div><h3>Methods</h3><p>Retrospective review of 100 consecutive eyes (91 patients) undergoing PFMS from four tertiary-referral glaucoma centers. Primary outcome were success rates. Secondary outcomes included: intraocular pressure (IOP), best-corrected visual acuity, medication, complications and postoperative interventions.</p></div><div><h3>Results</h3><p>100 eyes of 91 patients were included. Qualified and complete success rates (95 % CI) were 80 % (72–87 %) and 56 % (47–65 %) for Criterion A (IOP≤21 mmHg), 75 % (67–83 %) and 55 % (46–65 %) for Criterion B (IOP≤18 mmHg), 44 % (31–50 %) and 39 % (30–49 %) for Criterion C (IOP≤15 mmHg) and 10 % (5–16 %) and 10 % (5–16 %) for Criterion D (IOP≤12 mmHg) respectively. Mean IOP decreased from 23.8 mmHg to 14.1 mmHg (reduction of 35.3 %) after 36 months with a reduction of IOP-lowering agents from 2.52 (0 – 4) to 0.69 (0 – 3). 7 eyes (7 %) needed additional glaucoma surgery. Of these, 3 eyes underwent a glaucoma drainage device and 4 eyes had a trabeculectomy.36 eyes received additional procedures after PFMS implantation. Of these, 14 eyes (14 %) underwent a surgical revision and 12 eyes (12 %) a bleb needling procedure.</p><p>The complication rate was low: 1 eye developed corneal decompensation and underwent a DMEK after 24 months. 1 eye had a conjunctival erosion requiring a revision surgery. 2 eyes developed a postoperative uveitis that was treated with topical steroids and resolved without further damage. There were no hypotony-related complications.</p></div><div><h3>Conclusions</h3><p>PFMS surgery is a safe and effective procedure for reducing IOP and pressure-lowering therapy.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000546/pdfft?md5=2ca116a0573e875c789122ba620c16bc&pid=1-s2.0-S2950253524000546-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141696621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized fellow-eye controlled trial study of 1% terpinen-4-ol vs 1% tea tree oil eyelid cleanser for the treatment of meibomian gland dysfunction","authors":"Preamjit Saonanon ,&nbsp;Wannit Witoonchart ,&nbsp;Dusadee Charnvanich ,&nbsp;Somphob Thompho ,&nbsp;Kittichai Chaiseeda ,&nbsp;Yuda Chongpison ,&nbsp;Vannarut Satitpitakul","doi":"10.1016/j.ajoint.2024.100052","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100052","url":null,"abstract":"<div><h3>Purpose</h3><p>To compare the pre- and post-treatment differences in non-invasive tear breakup time (NITBUT) between a 1 % terpinen-4-ol (T4O) and a 1 % tea tree oil (TTO) eyelid cleanser</p></div><div><h3>Design</h3><p>A randomized controlled trial</p></div><div><h3>Method</h3><p>Thirty-three participants diagnosed with MGD were enrolled. All patients and the outcome evaluator were masked to the treatment allocation. One eye of each patient was randomly assigned to receive the T4O cleanser, while the fellow eye received the TTO cleanser. Baseline and eight week assessments included the collection of the ocular surface disease index (OSDI) questionnaire, NITBUT (in seconds), lipid layer thickness (in nanometers), ocular surface staining scores, and the presence of Demodex as cylindrical dandruff. The main outcome measurement was the pre- and post-treatment difference in NITBUT. Patient preference, safety, and tolerability were also assessed.</p></div><div><h3>Results</h3><p>There was a statistically significant increase in NITBUT in the T4O group (<em>n</em> = 30; 2.27 ± 1.09; 95 % confidence interval [CI]: 0.12–4.42; <em>p</em> = 0.038), but not in the TTO group (<em>n</em> = 30; 0.04 ± 1.10; 95 % CI: -2.19–2.11; <em>p</em> = 0.972). Both groups showed significant improvement in post-treatment ocular surface staining scores. Fifteen subjects (50 %) preferred TTO due to less cooling sensation experienced during application, nine (30 %) preferred T4O, and six (20 %) had no preference. No major adverse events were observed.</p></div><div><h3>Conclusion</h3><p>Eyelid cleaning with 1 % T4O in MGD for eight weeks was found to increase NITBUT with good tolerability, although it was less preferred compared to TTO.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000522/pdfft?md5=2046fe79ed7a02ef6c7d8de683495eba&pid=1-s2.0-S2950253524000522-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141605598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between endophthalmitis risk following a variety of intra-ocular procedures and defensin gene profile","authors":"Jonathan C. Park ,&nbsp;Angela Zhang ,&nbsp;Stefan DeGeus ,&nbsp;Michael Hogden ,&nbsp;Amanda Churchill ,&nbsp;Niels Crama ,&nbsp;Anneke den Hollander ,&nbsp;Wai-Ching Lam ,&nbsp;Peter Kertes ,&nbsp;Robert Devenyi ,&nbsp;Peng Yan ,&nbsp;Efrem D Mandelcorn ,&nbsp;Tina Felfeli ,&nbsp;David H Steel ,&nbsp;Richard Haynes","doi":"10.1016/j.ajoint.2024.100034","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100034","url":null,"abstract":"<div><h3>Objective</h3><p>Endophthalmitis is a sight threatening complication of intra-ocular procedures. It has been suggested that a predisposition to endophthalmitis is linked to a specific genotype in the human beta-defensin 1 (HBD-1) gene when previously analysed in a small UK cohort undergoing cataract surgery. We sought to test out this hypothesis in a larger international case: control study (centres in UK, Netherlands and Canada) following a variety of intraocular procedures.</p></div><div><h3>Design</h3><p>International case: control study</p></div><div><h3>Participants &amp; Methods</h3><p>660 individuals undergoing an intraocular procedure were recruited (165 cases of endophthalmitis and 495 controls). DNA was extracted. Single nucleotide polymorphisms, SNPs, rs11362, rs1800972 and rs2702877 in the HBD-1 gene were analysed (both individual genotypes and haplotypes were obtained).</p></div><div><h3>Results</h3><p>No associations were found when individual SNPs were analysed across the combined international cohort. However, analysis of the Toronto sub-cohort, showed a statistically significant association between the endophthalmitis cohort and the rs1800972 C allele (OR: 3.18, CI: 1.32 - 7.68, <em>p</em> = 0.01) and rs2702877 G allele (OR: 3.06, CI: 1.35 - 6.95, <em>p</em> = 0.017). No haplotype association was identified with endophthalmitis compared to control in both institution sub-cohorts and combined cohort analysis. A strong trend associating the rs1800972, rs11362 GG mini-haplotype with culture positive endophthalmitis groups across all groups was noted, but this did not reach statistical significance.</p></div><div><h3>Conclusions</h3><p>This is the first study to demonstrate a genetic link between a certain genetic profile (HBD-1 gene SNP variation) and endophthalmitis. Future pre-operative genetic testing could help identify patients at risk of endophthalmitis to guide invasive treatment options.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000340/pdfft?md5=9eca9cf861048b2fccef856a3f9dba2c&pid=1-s2.0-S2950253524000340-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141542906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual prognosis in retinoblastoma patients with multimodality treatments","authors":"Ratima Chokchaitanasin ,&nbsp;Nattawat Asawaworarit ,&nbsp;Wimwipa Dieosuthichat ,&nbsp;Suradej Hongeng ,&nbsp;Smart Pakakasama ,&nbsp;Usanarat Anurathapan ,&nbsp;Duantida Songdej ,&nbsp;Pongpak Pongphitcha ,&nbsp;Rangsima Aroonroch ,&nbsp;Rossukon Kaewkhaw ,&nbsp;Ekachat Chanthanaphak ,&nbsp;Duangnate Rojanaporn","doi":"10.1016/j.ajoint.2024.100051","DOIUrl":"10.1016/j.ajoint.2024.100051","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;This study evaluates factors associated with globe preservation and long-term visual outcomes according to clinical characteristics and treatment modalities in intraocular retinoblastoma patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;A retrospective review of medical records enrolled intraocular retinoblastoma patients between January 1, 2007, and June 30, 2020.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Setting: Single-centered.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Patient or study population: Intraocular retinoblastoma patients treated at Ramathibodi Hospital, Bangkok, Thailand.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Main outcome measure: A statistically significant factor associated with visual prognosis corresponds to baseline characteristics, staging, anatomical involvement, and multimodal treatments.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;86 patients (124 eyes) were included. Median age of disease bilaterality onset was significantly younger than unilaterality. Three-quarters of patients were in advanced stages (groups D or E in either ICRB or IIRC and up to cT2a from AJCC). Globe salvage rate was 54.0 % (67 eyes). ICRB Groups D-E, IIRC Groups D-E, and AJCC cT2a and more advanced stages are the globe removal-associated independent risk factors (adjusted odds ratio [AOR] [95 % CI] = 7.40 [1.36, 40.09], 8.33 [1.55, 44.73], 14.73 [1.55, 139.79], respectively). Compared to other classification, IIRC provided the highest statistical correlation from univariate analysis. IIRC Groups A-C is a good visual acuity-associated independent risk factor (AOR [95 % CI] = 4.64 [1.05, 20.43] and &lt;em&gt;P&lt;/em&gt; = 0.042). Macular involvement is a worse visual acuity-associated independent risk factor (AOR [95 % CI] = 0.14 [0.02, 0.82] and &lt;em&gt;P&lt;/em&gt; = 0.03). Systemic chemotherapy (86.29 %) is the mainstay treatment in our study and is the only good visual outcome-associated treatment. Subgroup analysis of all eyes receiving systemic chemotherapy reveals statistically significant preventive factors for globe removal for tumor staging with ICRB and IIRC groups A-C and AJCC stages cT1a–cT1b (odds ratio [95 % CI] = 15.75 [4.38, 56.65], 15.67 [4.34, 56.53], 9.97 [2.75, 36.18], respectively; &lt;em&gt;P&lt;/em&gt;=&lt;0.001) and prevents the worse visual outcome in these stages, (odds ratios [95 % CI] = 4.57 [1.28, 16.27], 6.61 [1.74, 25.11], and 7.50 [1.86, 30.16], respectively; &lt;em&gt;P&lt;/em&gt; =&lt; 0.05).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;All recent advanced clinical stagings are globe removal outcome-associated independent risk factors. IIRC staging is the best visual results predictor. IIRC Groups A-C were associated with a good visual outcome. Macular involvement tumors are strongly associated with poor visual outcome, despite successful globe preservation from multimodality treatment. Systemic chemotherapy remains a crucial globe-saving treatment and prevents worse vision–especially in","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 4","pages":"Article 100051"},"PeriodicalIF":0.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141707199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept","authors":"Miklos Schneider ,&nbsp;Yousif Subhi ,&nbsp;Jakob Bjerager ,&nbsp;Delila Hodzic-Hadzibegovic ,&nbsp;Oliver Niels Klefter ,&nbsp;Javad Nouri Hajari","doi":"10.1016/j.ajoint.2024.100049","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100049","url":null,"abstract":"<div><h3>Purpose</h3><p>Some patients with neovascular age-related macular degeneration (nAMD) do not respond to anti-VEGF treatment or develop tolerance or tachyphylaxis. If optimal treatment response is lacking with a given drug, switching to another is a common practice. The aim of this study was to report short-term outcomes of treatment switch to faricimab in real-world patients with nAMD resistant to both aflibercept and ranibizumab.</p></div><div><h3>Design</h3><p>Single-center, retrospective real-world cohort study.</p></div><div><h3>Methods</h3><p>Chart-review of 13 eyes of 13 multi-switch patients using electronic injection database, electronic medical records, and optical coherence tomography (OCT) data from May–September 2023.</p></div><div><h3>Results</h3><p>Faricimab treatment led to absence of fluid (subretinal, or both subretinal and intraretinal fluid) in 31% of the eyes and a reduction of fluid in 77% of the eyes at 4 weeks following the switch. The best-corrected visual acuity did not change significantly. No ocular or systemic safety events were observed.</p></div><div><h3>Conclusions</h3><p>Switching to faricimab seems a reasonable option in patients with nAMD who were previously resistant to both aflibercept and ranibizumab treatment. We noted a high rate of morphological response and improvement in anatomical parameters, with nearly one-third of the patients achieving dry macula after just one injection. No change in BCVA was seen. No safety issues were noted. The durability of these results warrants additional investigations.</p></div><div><h3>Trial registration</h3><p>ClinicalTrials.gov, registration number: NCT06231121, date of registration: 21/01/2024, retrospectively registered.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000492/pdfft?md5=d028d60b60e49757e831eb6ae9af7a20&pid=1-s2.0-S2950253524000492-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141605599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid assessment of avoidable blindness (RAAB): A 15-year follow-up in Gegharkunik province of Armenia","authors":"Aida Giloyan ,&nbsp;Vahe Khachadourian ,&nbsp;Tsovinar Harutyunyan ,&nbsp;Naira Khachatryan ,&nbsp;Varduhi Petrosyan","doi":"10.1016/j.ajoint.2024.100048","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100048","url":null,"abstract":"<div><h3>Purpose</h3><p>This study assessed the changes in the prevalence of visual impairment (VI)/blindness, cataract surgical coverage (CSC), visual outcome after cataract surgery, and main barriers to cataract surgery among the population aged 50 years and older in Gegharkunik province of Armenia from 2003 - 4 to 2019.</p></div><div><h3>Design</h3><p>A cross-sectional study.</p></div><div><h3>Methods</h3><p>A multi-stage cluster sampling technique was used to conduct Rapid Assessment of Cataract Surgical Services (RACSS) and Rapid Assessment of Avoidable Blindness (RAAB) surveys in 2003–4 and 2019, respectively. Overall, 56 clusters (40 people in each cluster) were selected for RACSS, and 24 clusters (50 people in each cluster) for RAAB. Both surveys collected data on participants’ demographics, presenting/pinhole visual acuity (PVA/PinVA), the principal cause of VI, CSC, and barriers to cataract surgery.</p></div><div><h3>Results</h3><p>Overall, 1,787 people participated in RACSS and 1,099 people in RAAB. Between 2003–4 and 2019, age- and sex-adjusted prevalence of bilateral blindness decreased from 2.0 % to 1.4 % while severe VI decreased from 5.2 % to 2.2 % and moderate VI from 16.0 % to 7.3 %. Untreated cataract contributed to 71.9 % and 40.9 % of all blindness cases in 2003–4 and 2019, respectively. The CSC at the threshold &lt;6/18 improved from 23.7 % in 2003–4 to 64.8 % in 2019. Both surveys mentioned the cost as the most common barrier to cataract surgery.</p></div><div><h3>Conclusion</h3><p>Despite substantial improvements, cataract remained the main cause of blindness in the province. Increasing financial coverage of cataract surgeries and improving the quality of surgeries could increase their utilization of services and help improve visual outcomes in the population.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000480/pdfft?md5=cd8d96b767bf6fae8acd402006f50c57&pid=1-s2.0-S2950253524000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teprotumumab-associated aural fullness and ageusia: A case report of persistent complications following thyroid eye disease treatment","authors":"David A. Hsiou,&nbsp;Jesse A. Terrell,&nbsp;Ryan P. Nolan,&nbsp;Lucy I. Mudie,&nbsp;Michael T. Yen MD","doi":"10.1016/j.ajoint.2024.100047","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100047","url":null,"abstract":"<div><h3>Purpose</h3><p>As an inhibitor of the insulin-like growth factor-1 (IGF-1) receptor, teprotumumab is utilized in the treatment of thyroid eye disease (TED) in which there is overexpression of IGF-1 receptors by orbital fibroblasts. Clinical trials and additional studies have brought the otologic side effects of the drug to attention. Discontinuing the drug leads to resolution in some patients, whereas others report chronic symptoms, including hearing loss. Gustatory side effects have not been elucidated to the same degree, and there are no specific recommendations on how to screen for or address otologic or gustatory complications of teprotumumab. This case report details the course of a patient with prolonged aural fullness and ageusia following teprotumumab treatment.</p></div><div><h3>Design and Methods</h3><p>Case report.</p></div><div><h3>Results</h3><p>A 71-year-old woman presenting with thyroid eye disease underwent seven cycles of teprotumumab infusion therapy. Her symptom profile, including aural fullness and ageusia, led to treatment cessation prior to completion of her final infusion. Following this treatment course, her thyroid eye disease clinical activity score improved and almost all her medication-associated adverse effects resolved.</p></div><div><h3>Conclusion</h3><p>This report highlights the first documented case of ageusia, and an unusually protracted course of aural fullness, with teprotumumab use. The case affirms the value of otologic and gustatory screening and continued evaluations before, during, and after receiving teprotumumab, and further characterizes aural fullness and ageusia as potential lasting consequences of therapy.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 3","pages":"Article 100047"},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000479/pdfft?md5=33cd94bc899aa923a6efceea22fd9814&pid=1-s2.0-S2950253524000479-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal cord-blood platelet-rich plasma for dry-AMD: Safety profile","authors":"Maria Cristina Savastano,&nbsp;Luciana Teofili,&nbsp;Stanislao Rizzo","doi":"10.1016/j.ajoint.2024.100045","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100045","url":null,"abstract":"<div><p>This report was prepared to promote the safety results of intravitreal cord-blood platelet-rich plasma (CB-PRP) use for dry-age-related macular degeneration (dry-AMD) as possible regenerative therapy. We believe that the safety data is important to convey while waiting for the results of possible efficacy. A dissemination of safety information in the use of CB-PRP for intravitreal use could help us with future collaborations and be able to study its real potential that only large numbers can provide. We believe in the regenerative power of CB-PRP. Moreover, funding for this research is completely absent. We trust that the Editor may consider it.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 2","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000455/pdfft?md5=36a641673c02cb62940da7d2aa444d86&pid=1-s2.0-S2950253524000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141480167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}